The 3rd STING and TLR-Targeting Therapies Summit is coming at a timely inflection point in this field.
With multiple TLR agonists moving into the clinic, STING agonists exposing new challenges, multiple approvals on the horizon, and more novel targets and combinations currently undergoing exciting pre-clinical validation than ever before, this unique and highly anticipated industry-focused meeting will unite experts in innate immunity to overcome the barriers it faces and accelerate clinical breakthrough.
Returning in-person to the biopharma hub of Boston, 30+ expert speakers will take you through case-study led presentations, juicy panel discussions and live Q and A's, all tailored to suit your TLR, STING and other PRR targeting needs.
Gain connections and insights to plan how to optimize the development of your innate immune agonists into the clinic and overcome obstacles that may impede the delivery of more selective, better-tolerated medicines to improve survival rates in difficult-to-treat cancers.
Industry Pricing - Conference + Focus Day: USD 3998.0,
Industry Pricing - Conference Only: USD 2999.0
Speakers: Michael J. Newman Founder and Chief Scientific Officer Indaptus Therapeutics, Kate Fitzgerald Professor - Program in Innate Immunity, Division of Infectious Diseases and Immunology UMass Medical School, Robert Andtbacka Chief Medical Officer Seven and Eight Biopharmaceuticals, Shannon Morris Vice President of Clinical Development Istari Oncology, Babette Schade Head of Biology Lab and Principal Scientist TargImmune Therapeutics, Diwakar Davar Assistant Professor - Phase, Therapeutics and Melanoma University of Pittsburgh, Mingchao Kang Group Lead, Head Technology Platform Ambrx, Joshi Ramanjulu Senior Director and Head of Project Leader Group, Innate Immunity Research Unit and Senior Fellow GlaxoSmithKline, John Flygare Senior Principal Scientist Merck and Co, Roxana Schillaci Senior Researcher Instituto de Biologia y Medicina Experimental, Buenos Aires (IBYME), Adi Diab Associate Professor - Melanoma Medical Oncology MD Anderson Cancer Center, Arthur Krieg Chief Executive Officer Checkmate Pharmaceuticals, Sonia Macia Director - Medical Highlight Therapeutics, Jim Appleman Chief Scientific Officer, CoFounder, Director and Senior Vice President - Research and Development Primmune Therapeutics, Matt Booty Lead Scientist Spring Discovery, Brian Horsburgh Chief Executive Officer Activate Therapeutics, Lei Jin Assistant Professor - Medicine University of Florida, Bettina Werle Chief Scientific Officer Tollys, Tracy Kuo Senior Director - Biology and Translational Science Tallac Therapeutics, Peter DeMuth Vice President - Research Elicio Therapeutics, Stuart Hughes Chief Executive Officer Pathios Therapeutics, Juho Jalkanen Chief Development Officer Faron Pharmaceuticals, Karim Kasmi Senior Principal Scientist Boehringer Ingelheim, Swaminathan P. Iyer Professor of Medicine, Department of Lymphoma/Myeloma MD Anderson Cancer Center, Austin Bigley Vice President and Director of Research and Development Indapta Therapeutics, Timo K. van den Berg Senior Director ImmunoOncology Byondis, Elsa Sanchez-Lopez Assistant Professor Department of Orthopaedic Surgery School of Medicine University of California San Diego, Kamal Puri Chief Scientific Officer Oncoresponse, Jasper Mullenders Director Translation Biology Scenic Biotech, Andrew Miller Co-founder and Vice President - Immunology and Operations Apros Therapeutics
Time: 10:00 - 17:00